Timo Soeterik

33 Active Surveillance: Patient Selection RESULTS Patient population A total of 1181 patients were evaluated; this included 181 patients with incidental tumours who were subsequently excluded. The remaining 1000 patients with biopsy-detected PCa included 79 patients (8%) with one or more missing baseline values that were imputed. In this cohort, approximately half of the patients would not meet the PRIAS criteria: 490/1000 (49%). Among all the separate criteria, PSAD <0.2 ng/ml/ml was most often not met (31%; Figure 1). The baseline characteristics for PRIAS-eligible and PRIAS-ineligible patients are provided in Table 1. TABLE 1. Baseline characteristics PRIAS-eligible PRIAS-ineligible p No. of patients 510 490 Age (years) 66.3 ± 0.3 68.2 ± 0.3 <0.001 PSA (ng/ml) 6.1 ± 1.9 10.2 ± 5.5 <0.001 PSA density a (ng/ml/ml) 0.12 ± 0.04 0.25 ± 0.14 <0.001 cT-stage b (%) T1c T2a T2b T2c T2 T3 407 (80) 40 (8) 4 (1) 6 (1) 53 (10) 0 (0) 381 (78) 24 (5) 10 (2) 9 (2) 55 (11) 11 (2) Total no. biopsy cores 9.2 ± 1.9 8.9 ± 2.0 0.009 No. positive cores 1.3 ± 0.4 2.1 ± 1.3 <0.001 Gleason score 2 + 2 2 + 3 / 3 + 2 3 + 3 3 + 4 4 + 3 2 (0) 3 (1) 505 (99) 0 0 3 (1) 7 (1) 434 (89) 42 (9) 4 (1) a PSA density: PSA divided by prostate volume (assessed with transrectal ultrasonography or MRI). b Clinical stage based on digital rectal examination. *All variables are in number (%) or mean ± SD. *Percentages may not total 100% due to rounding. 2